Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not they moved in tandem with the market in January. One month of strong (or poor) returns means little in the grand scheme of things.To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Phar ...

Group 1: Tilray Brands - Tilray has been a speculative investment based on hopes for marijuana legalization in the U.S., but the stock has declined over 94% in five years [3][4] - The company has diversified into alcoholic beverages, yet its financial situation remains precarious, with a market cap below $1 billion [5] - Continuous cash burn and losses indicate a lack of recovery potential for Tilray [5] Group 2: Moderna - Moderna has missed opportunities to diversify beyond its COVID vaccine revenue, focusing instead on COVID-related products [6] - The company expects revenue between $1.5 billion and $2.5 billion for the year, a reduction of approximately $1 billion from previous expectations [8] - There are no clear catalysts for growth, making it a stock to avoid even if prices decline further [9] Group 3: Plug Power - Plug Power's stock has plummeted from over $70 in 2021 to under $2, reflecting investor skepticism [10] - The company faces significant financial challenges, with $94 million in cash and operating losses exceeding $720 million in the first nine months of 2024 [12] - The sustainability of its operations is in question, suggesting that investors should consider other growth opportunities [12]

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 14, 2025, might help the stock move higher if these key numbers are better than exp ...

We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat estimates by 101.59%.The Zacks Consensus Estimate for sales and earnings is pegged at $955.23 million and at a loss of $2.65 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping MRNA’s Upcomi ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure ...

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 29, 2025 /PRNewswire/ -- USA News Group News Commentary – As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, which could have major ramifications on the standard of living of Americans and the world. Healthcare industry leaders are rapidly adopting artificial intelligence (AI) tech into their operatio ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%.Prior to today's trading, shares of the biotechnology company had gained 3.19% over the past month. This has outpaced the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% in that time.Market participants will be cl ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?Shares of Moderna (MRNA -2.31%) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence.The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic. However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (MRNA -2.31%) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.In that vein, let's learn about the three most important things you sh ...

Core Insights - Moderna is developing a vaccine for norovirus, with a large phase three trial currently underway, and results expected as early as late 2024 or 2026 [2][10] - The current winter has seen a significant increase in norovirus cases, with a 36% rise in outbreaks compared to the previous season, and twice as many positive tests reported in January [4][3] - The vaccine candidate targets three genotypes of norovirus, but does not include the genotype responsible for most infections this year [5][6] Company Strategy - The primary goal of the vaccine is not to completely prevent norovirus but to reduce the severity of symptoms and prevent hospital visits [7] - The company aims to vaccinate vulnerable populations, particularly seniors aged 65 and above, who are at higher risk of complications from norovirus [8] - Other target groups include healthcare workers, daycare workers, and individuals on cruise ships, as these populations are frequently exposed to norovirus [9][10] Market Considerations - Investors are skeptical about the commercial viability of the vaccine, contingent on its effectiveness, with a focus on protecting those in nursing homes and cruise passengers [10] - The vaccine is not currently being tested in children, but if successful in adults, further studies in children will be necessary [10]